Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses the role and future directions of the European Society for Blood and Marrow Transplantation (EBMT). The hematopoietic cell transplantation field faces new challenges with the introduction of cellular therapy and gene therapy products. These new therapies have similarities with the practice of hematopoietic cell transplantation; however, there are striking differences between transplant and the manufacture process and administration of CAR T-cells. Even though EBMT has significant and useful expertise in transplantation, Prof. Chabannon emphasizes the need to collaborate with other groups. Additionally, Prof. Chabannon believes that EBMT is well-positioned to be a major organization in the field. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).